stoxline Quote Chart Rank Option Currency Glossary
TRACON Pharmaceuticals, Inc. (TCON)
0.97  -0.03 (-2.99%)    06-13 16:00
Open: 0.9972
High: 1
Volume: 161,662
Pre. Close: 0.9999
Low: 0.8516
Market Cap: 3(M)
Technical analysis
2024-06-13 4:46:38 PM
Short term     
Mid term     
Targets 6-month :  1.78 1-year :  2.4
Resists First :  1.52 Second :  2.05
Pivot price 1.24
Supports First :  0.66 Second :  0.54
MAs MA(5) :  1.05 MA(20) :  1.3
MA(100) :  3.59 MA(250) :  4.17
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  26.8 D(3) :  16.7
RSI RSI(14): 25.2
52-week High :  14.73 Low :  0.66
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TCON ] has closed above bottom band by 10.9%. Bollinger Bands are 77.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1 - 1.01 1.01 - 1.01
Low: 0.84 - 0.84 0.84 - 0.85
Close: 0.96 - 0.97 0.97 - 0.98
Company Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Headline News

Thu, 13 Jun 2024
TRACON Pharmaceuticals (NASDAQ:TCON) Upgraded to Buy at - Defense World

Sun, 02 Jun 2024
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Short Interest Down 18.9% in May - Defense World

Wed, 15 May 2024
David Lazar Joins TRACON Pharmaceuticals as Chief Business Officer - - TipRanks

Tue, 14 May 2024
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance

Tue, 14 May 2024
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript - Seeking Alpha

Fri, 12 Apr 2024
UTHR: 3 Promising Biotech Stocks Driving Weekly Gains -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.62e+006 (%)
Held by Institutions 2.2 (%)
Shares Short 24 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.78e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 14.3 %
Operating Margin -3 %
Return on Assets (ttm) 212 %
Return on Equity (ttm) -19.8 %
Qtrly Rev. Growth 1.214e+007 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 106.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 6 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -1.83
Stock Dividends
Dividend 0
Forward Dividend 124050
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android